[Torasemide (LUPRAC): a review of its pharmacological and clinical profile].
Loop diuretics potently excrete water and electrolytes and therefore have been widely prescribed for the treatment of various kinds of edema for a long time. The potent diuretic action of loop diuretics, however, often causes hypokalemia, and therefore potassium sparing diuretics have also been supplied as a concomitant drug. Torasemide (LUPRAC), a novel diuretics, shows not only an effective loop diuretic action but also a potassium sparing action due to its anti-aldosteronergic effect. Torasemide also has a high bioavailability and is only slightly influenced by meals in humans. In addition, its pharmacodynamic features contribute to its stable diuretic action without any individual differences. In animal experiments, torasemide showed about a tenfold more potent diuretic action in comparison with furosemide, an authentic loop diuretic. On the one hand, the increase in the urinary potassium excretion by torasemide was relatively slight compared to the increase in urinary sodium excretion and, as a result, the urinary sodium to potassium (Na+/K+) ratio increased. The diuretic profile of torasemide was equal to that of the concomitant use of furosemide and an anti-aldosteronergic drug, spironolactone. Torasemide showed a significant efficacy and safety in comparison with furosemide in the patients with edema in both domestic and foreign clinical studies. Moreover, torasemide also showed a decreased rate of cardiac death in comparison to furosemide in patients with chronic heart failure in a large-scale clinical study (TORIC Study). The difference in cardiac death between these two diuretics has been suggested to depend on the anti-aldosteronergic effect of torasemide. In Japan, no new loop diuretics have been developed in over 10 years. Torasemide is therefore expected to be useful as an effective diuretic for diseases with edema.
Kido
H
H
Welfide Corporation, Drug Development Laboratories, 955 Koiwai, Yoshitomi-cho, Chikujo-gun, Fukuoka 871-8550, Japan. ac39586@welfide.co.jp
Ohtaki
Y
Y
D000818:Animals; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000494:pharmacology* / Q000627:therapeutic use; D004489:Edema, Cardiac / Q000188:drug therapy; D005665:Furosemide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D000451:Mineralocorticoid Receptor Antagonists; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D000077786:Torsemide
D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D013449:Sulfonamides; D005665:Furosemide; D000077786:Torsemide